Journals / MN Kardiyoloji / 2013 / Cilt: 20 - Sayı: 2

Effect of trimetazidine therapy on echocardiographic parameters and NT-ProBNP levels in diabetic and nondiabetic patients with ischemic heart failure

Trimetazidin tedavisinin iskemik kalp yetersizliği olan diyabetik ve diyabetik olmayan hastalarda ekokardiyografik parametreler ve NT-ProBNP düzeyine etkisi

Pages
59–70
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Three-month trimetazidine treatment improves exercise tolerance and left ventricular systolic functions in patients with ischemic left ventricular dysfunction.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: As prevalance of diabetics and heart failure patients increases these associate conditions may contribute to the failure of classic therapeutic strategies in ischemic heart diseases.
📊
Key Findings & Data:Trimetazidine shifts the preference of myocytes for energy substrate away from fatty acid to glucose metabolism.
💡
Conclusion & Impact:Conclusion: Three-month trimetazidine treatment improves exercise tolerance and left ventricular systolic functions in patients with ischemic left ventricular dysfunction.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: As prevalance of diabetics and heart failure patients increases these associate conditions may contribute to the failure of classic therapeutic strategies in ischemic heart diseases. Trimetazidine shifts the preference of myocytes for energy substrate away from fatty acid to glucose metabolism. Metabolic therapy offers concrete help in the management of coronary artery disease and heart failure. Brain natriüretic peptides are well established as an independent predictor of prognosis in mild to moderate chronic heart failure. The purpose of this study was to investigate the changes in plasma NT-ProBNP levels and left ventricular functions during a three month therapy with trimetazidine in ischemic heart failure patients. Material and Method: The study included 33 patients (2 females, 31 males; mean age 62±9 years) with ischemic heart failure. Trimetazidine was initiated with a dose of 60 mg/day to continue theraphy at least 3 months. Blood samples were obtained, transthoracic echocardiography and exercise stress test was performed at enrollment and after three months. Plasma B-type natriuretic peptide levels, left ventricular systolic and diastolic functions, symptoms and functional capacity were assessed. Results: After three months, significant improvement detected in exertional dyspnea (p<0.05), exertional angina (p<0.05), left ventricular end systolic volume (p<0.001), end systolic diameter (p<0.01), ejection fraction (p<0.001), myocardial performans index (p<0.05), global wall motion score index (p<0.001), septal annuler systolic myocardial velocity (p<0.05) maximum egzercise time (p<0.05) and maximum metabolic equivalent parameters (p<0.005). No significant improvement detected in left venticul diastolic function parameters. Whereas a trend to be significantly decreasing is observed in B-type natriuretic peptide levels (p>0.05). Conclusion: Three-month trimetazidine treatment improves exercise tolerance and left ventricular systolic functions in patients with ischemic left ventricular dysfunction.

Özet

Amaç: Diyabet ve kalp yetersizliği prevalansının artışıyla birlikte iskemik kalp hastalıklarında klasik tedavi stratejileri yetersiz kalmaktadır. Trimetazidin miyositlerdeki enerji kaynağını yağ asidi metabolizmasından glukoz metabolizmasına kaydırmaktadır. Metabolik tedavi koroner arter hastalığı ve kalp yetersizliği tedavisinde ek fayda sağlar. Beyin natriüretik peptidler hafif kalp yetersizliğinde prog- nozun bağımsız öngörücüsü olarak belirlenmiştir. Bu çalışmada iskemik kalp yetmezliği hastalarında 3 aylık trimetazidin tedavisinin plazma NT-ProBNP düzeyi ve sol ventrikül fonksiyonlarına etkisi değerlendirildi. Gereç ve Yöntem: Çalışmaya iskemik kalp yetersizliği olan 33 hasta (2 kadın, 31 erkek; ortalama yaş 62±9) alındı. Trimetazidine 60 mg/gün dozunda en az 3 ay devam edilmek üzere başlandı. Kan örnekleri alındı, transtorasik ekokardiyografi ve egzersiz stres testi 3 aylık tedaviden önce ve sonra yapıldı. Plazma natriüretik peptid seviyeleri, sol ventrikül sistolik ve diyastolik fonksiyonları, semptomlar ve egzersiz toleransı değerlendirildi. Bulgular: Üç aylık trimetazidin tedavisi sonrası, eforla nefes darlığı (p<0,05), eforla göğüs ağrısı (p<0,05), sol ventrikül sistol sonu hacmi (p<0,001) , sistol sonu çapı (p<0,01), ejeksiyon fraksiyonu (p<0,001), miyokardiyal performans indeksi (p<0,05), global duvar hareket skor indeksi (p<0,001), septal anular sistolik miyokardiyal hızı (p<0,05), maksimum egzersiz süresi (p<0,05) ve maksimum metabolik eşdeğerlik parametrelerinde (p<0,005) anlamlı düzelme görüldü. Sol ventrikül diyastolik fonksiyon parametrelerinde düzelme izlenmedi. Bununla beraber natriüretik peptid düzeylerinde anlamlılığa yaklaşan oranda azalma saptandı (p=0,054). Sonuç: Üç aylık trimetazidin tedavisinin iskemik sol ventrikül fonksiyon bozukluğu olan hastalarda egzersiz toleransı ve sol ventrikül sistolik fonksiyonlarını düzelttiği gösterilmiştir.

🔖

Cite This Article

ŞENSOY, B., YEŞİLBURSA, D., ŞENSOY, N. Ö., ŞENTÜRK, T., AKTÜRK, Y., ÖZBEK, C., AYDINLAR, A. (2013). Effect of trimetazidine therapy on echocardiographic parameters and NT-ProBNP levels in diabetic and nondiabetic patients with ischemic heart failure. MN Kardiyoloji, Cilt: 20 - Sayı: 2, 59–70. https://ajindex.com/articles/297405

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Pericle Di Napoli, Alfonso A Taccardi: “Trimetazidine: the future of cardiac function”. Future Cardiol 2009:5
  2. 24 2. Frenneaux MP. Autonomic changes in patients with heart failure and in post-myocardial infarction patients. Heart 2004
  3. 55 3. Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, vonScheidt W. Role of brain natriuretic peptide in risk stratification of pa-tients with congestive heart failure. J Am Coll Cardiol 2001
  4. 41 4. Kim SH, Kim JS, Baek KK, et al. Role of NT-proBNP in evaluation of functional status in congestive heart failure. Korean Circ J 2004
  5. Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of NT-pro-natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994
  6. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997
  7. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A tiolase. Circ Res 2000
  8. 8 8. Harpey C, Clauser P, Labrid C, Freyria JL, Poirier JP. Trimetazidine, a cellular anti-ischemic agent. Cardiovasc Drug Rev 1989
  9. 312 9. Stanley WC, Lopaschuck GD, Hall JL, Mccormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions: potential for pharmacological interventions. Cardiovasc Res 1997
  10. 57 10. Detry JM, Sellier P, Pennaforte S, Cokkinos D, Dargie H, Mathes P. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Br J Clin Pharmacol 1994
  11. Szwed H, Hradec J, Preda I. Anti-ischaemic efficacy and tolerability of trimetazidine administered to patients with angina pectoris: results of three studies. Coron Artery Dis 2001
  12. 12 (Suppl. 1):25-8 12. Belardinelli R, Solenghi M, Volpe L, Purcaro A. Trimetazidine improves endothelial dysfunction in chronic heart failure: an antioxidant effect. Eur Heart J 2007
  13. 8 13. Marzilli M, Affinito S, Focardi M. Changing scenario in chronic ischemic heart disease: therapeutic implications. Am J